Verve Therapeutics, Inc.
Verve Therapeutics, Inc. (VERV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
verv · stock forecast · 13 analysts (3M) · FMP · updated Nov 10, 2025
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Hold
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$30.00
Consensus
$18.00
+61.7% upside
Low
$13.00
Median: $14.5 · Last Close: $11.13
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$18.00
61.7% upside
High Target
$30
169.5%
Low Target
$13
16.8%
Current Price
$11.13
as of today
Based on analyst price targets, the VERV stock price prediction for the next 12 months ranges from $13 to $30. The consensus VERV price forecast of $18.00 implies 61.7% upside from the current price of $11.13.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $11.09 | ↓ 0.35% |
1-day model range: $11.08–$11.1. Peak: $11.1 (-0.35%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · VERV · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-27 | BMO Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-06-18 | LifeSci Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-06-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-06-18 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-06-17 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2025-06-17 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2025-04-15 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-04-15 | Guggenheim | Maintains | Buy→Buy |
| 2025-04-15 | William Blair | Maintains | Outperform→Outperform |
| 2025-04-15 | Cantor Fitzgerald | Upgrade ↑ | Neutral→Overweight |
Wall Street analysts have recently issued updated ratings on Verve Therapeutics, Inc. (VERV) stock. Of the recent 44 rating actions, 2 were upgrades and 6 were downgrades. 13 analysts currently cover VERV.
Analyst Recommendation Trends
VERV analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$45M
↑ 200.3% YoY
Revenue Next Year
$16M
↓ 64.3% YoY
EPS This Year
$-2.51
EPS Next Year
$-3.11
↑ 23.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast VERV EPS of $-2.51 for the current fiscal year, based on estimates from 5 analysts. The VERV revenue forecast is $45M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The VERV stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VERV price target is $18.00 (+61.7% upside), with an analyst consensus of Hold.
The VERV short-term stock prediction for tomorrow is $11.09 (-0.35%).
Verve Therapeutics, Inc. trades on NASDAQ under the ticker VERV. The VERV stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 31% of covering analysts.
Frequently asked questions
VERV forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month VERV price target is $18.00, with a high forecast of $30.00 and a low of $13.00. The median price target is shown in the chart above when available. This implies +61.7% potential upside from the current price of $11.13.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.